Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03634969 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03634969 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 50 participants.
The verdict
NCT03634969, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.
Interventions
- DRUG BMS-986224
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2019-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03634969
The ClinicalTrials.gov registry entry for NCT03634969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986224 is the first listed.
NCT03634969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03634969 about?
NCT03634969 is a clinical study titled "An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants". The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.
What is the current status of trial NCT03634969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-08-14. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03634969?
The interventions under investigation include: BMS-986224 (DRUG).
Who is sponsoring clinical trial NCT03634969?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.